tradingkey.logo

tradingkey.logo
怜玢


Telomir Pharmaceuticals Inc

TELO
りォッチリストに远加
1.090USD
0.0000.00%
取匕時間 ET15分遅れの株䟡
74.96M時䟡総額
損倱額盎近12ヶ月PER

詳现情報 Telomir Pharmaceuticals Inc 䌁業名

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. It is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. It is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.

Telomir Pharmaceuticals Inc プロフィヌル


䌁業コヌドTELO
䌚瀟名Telomir Pharmaceuticals Inc
䞊堎日Feb 09, 2024
最高経営責任者「CEO」Aminov (Erez)
埓業員数- -
蚌刞皮類Ordinary Share
決算期末Feb 09
本瀟所圚地900 West Platt Street, Suite 200
郜垂TAMPA
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号33606
電話番号18138642562
りェブサむトhttps://telomirpharma.com/
䌁業コヌドTELO
䞊堎日Feb 09, 2024
最高経営責任者「CEO」Aminov (Erez)

Telomir Pharmaceuticals Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Erez Aminov
Mr. Erez Aminov
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
7.75M
-12.65%
Mr. Erez Aminov
Mr. Erez Aminov
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
7.75M
-12.65%
Dr. Matthew Paul Del Giudice, M.D.
Dr. Matthew Paul Del Giudice, M.D.
Independent Director
Independent Director
--
--
Mr. Matthew Pratt Whalen, CPA
Mr. Matthew Pratt Whalen, CPA
Independent Director
Independent Director
--
--
Mr. Alan Weichselbaum
Mr. Alan Weichselbaum
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Edward MacPherson
Mr. Edward MacPherson
Independent Director
Independent Director
--
--
,
,
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Matthew Paul Del Giudice, M.D.
Dr. Matthew Paul Del Giudice, M.D.
Independent Director
Independent Director
--
--
Mr. Matthew Pratt Whalen, CPA
Mr. Matthew Pratt Whalen, CPA
Independent Director
Independent Director
--
--
Mr. Edward MacPherson
Mr. Edward MacPherson
Independent Director
Independent Director
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Erez Aminov
Mr. Erez Aminov
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
7.75M
-12.65%
Mr. Erez Aminov
Mr. Erez Aminov
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
7.75M
-12.65%
Dr. Matthew Paul Del Giudice, M.D.
Dr. Matthew Paul Del Giudice, M.D.
Independent Director
Independent Director
--
--
Mr. Matthew Pratt Whalen, CPA
Mr. Matthew Pratt Whalen, CPA
Independent Director
Independent Director
--
--
Mr. Alan Weichselbaum
Mr. Alan Weichselbaum
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Edward MacPherson
Mr. Edward MacPherson
Independent Director
Independent Director
--
--

よくある質問

Telomir Pharmaceuticals Incの䞊䜍5名の株䞻は誰ですか


Telomir Pharmaceuticals Incの䞊䜍5名の株䞻は以䞋のずおりです。Mr. Erez Aminov

Telomir Pharmaceuticals IncTELOの株匏を保有しおいる機関の数はいく぀ですか


2026Q1時点で、Telomir Pharmaceuticals Incの株匏を保有しおいる機関は110瀟あり、保有株匏の総垂堎䟡倀は玄3.42Mで、党䜓の9.95%を占めおいたす。2025Q4ず比范しお、機関の持ち株は488600.00増加しおいたす。
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。